GRAIL/$GRAL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About GRAIL
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
Ticker
$GRAL
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
1,000
ISIN
US3847471014
Website
GRAIL Metrics
BasicAdvanced
$1.6B
-
-$58.52
-
-
Price and volume
Market cap
$1.6B
52-week high
$63.99
52-week low
$12.33
Average daily volume
1.4M
Financial strength
Current ratio
9.705
Quick ratio
9.255
Long term debt to equity
2.127
Total debt to equity
2.665
Profitability
EBITDA (TTM)
-496.363
Gross margin (TTM)
-58.18%
Net profit margin (TTM)
-1,464.53%
Operating margin (TTM)
-500.29%
Effective tax rate (TTM)
8.16%
Revenue per employee (TTM)
$130,000
Management effectiveness
Return on assets (TTM)
-11.99%
Return on equity (TTM)
-62.22%
Valuation
Price to revenue (TTM)
10.86
Price to book
0.63
Price to tangible book (TTM)
3.55
Price to free cash flow (TTM)
-3.036
Free cash flow yield (TTM)
-32.94%
Free cash flow per share (TTM)
-1,429.28%
Growth
Revenue change (TTM)
30.47%
Earnings per share change (TTM)
21.85%
What the Analysts think about GRAIL
Analyst ratings (Buy, Hold, Sell) for GRAIL stock.
Bulls say / Bears say
GRAIL's Galleri test has shown positive outcomes in recent registrational studies, indicating potential for early cancer detection and market adoption. (finance.yahoo.com)
Institutional investors like Westwood Holdings Group Inc. have taken significant positions in GRAIL, reflecting confidence in the company's growth prospects. (marketbeat.com)
Analysts have raised price targets for GRAIL, with Canaccord Genuity Group increasing their objective from $32.00 to $43.00, suggesting optimism about the company's future performance. (marketbeat.com)
GRAIL's stock price experienced a significant drop of 67% on December 30, 2024, indicating potential volatility and investor concerns. (marketbeat.com)
The company reported a Q1 loss despite revenue growth, leading to a 20.75% decline in share value, which may raise questions about profitability. (fastbull.com)
Insider selling activity, such as President Joshua J. Ofman selling 9,692 shares, might signal lack of confidence among executives. (insidertrades.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
GRAIL Financial Performance
Revenues and expenses
GRAIL Earnings Performance
Company profitability
GRAIL News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for GRAIL stock?
GRAIL (GRAL) has a market cap of $1.6B as of July 11, 2025.
What is the P/E ratio for GRAIL stock?
The price to earnings (P/E) ratio for GRAIL (GRAL) stock is 0 as of July 11, 2025.
Does GRAIL stock pay dividends?
No, GRAIL (GRAL) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next GRAIL dividend payment date?
GRAIL (GRAL) stock does not pay dividends to its shareholders.
What is the beta indicator for GRAIL?
GRAIL (GRAL) does not currently have a Beta indicator.